Avitinib maleate is a third-generation, irreversible, and orally active selective EGFR inhibitor. It has IC50 values of 0.18 nM against both EGFR L858R and EGFR T790M, and 7.68 nM against wild-type EGFR. It is also a BTK inhibitor, inducing apoptosis and inhibiting BTK phosphorylation in mantle cell lymphoma. It exhibits anticancer effects.
- Third-generation, irreversible, and orally active selective EGFR inhibitor.
- Potent against EGFR L858R, EGFR T790M, and wild-type EGFR.
- BTK inhibitor.
- Induces apoptosis.
- Inhibits phosphorylation of BTK in mantle cell lymphoma.
- Exhibits anticancer effects.